Alzheimer-kór: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• APOE 16
• MAPT 2
• APP 1
• NRF2 0
• NLRP3 0
• TREM2 0
• AKT 0
• BDNF 0
• TDP-43 2
• PI3K 0
• BACE1 0
• GLP-1 1
• MAPK 0
• PPAR 0
• AMPK 0
• mTOR 0
• PSEN1 1
• STING 0
• ERK 0
• NMDA 1
• SNCA 0
• TLR4 0
• JNK 0
• SIRT1 0
• CTNNB1 0
• STAT3 0
• TP53 0
• TNF 0
• HDAC 0
• HIF-1 0
• SGLT2 0
• HMGB1 0
• GPX4 0
• IL-1 0
• PCSK9 0
• COX-2 0
• HSP90 1
• C9orf72 0
• DPP-4 0
• PINK1 0
• IL-17 0
• TFEB 0
• IL-6 0
• PD-L1 0
• VEGF 0
• YAP 0
• AQP4 0
• CD33 0
• IGF1R 0
• MMP-9 0
• CCR5 0
• EGFR 0
• FTO 0
• GBA1 0
• GIP 0
• JAK 0
• KEAP1 0
• PARP 0
• PD-1 0
• ACE2 0

5551 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Neuroinflammation and Virus Imaging for Smart Therapeutic Approaches (NEUROVISTA)

  Umea Universitet· Umea, Svédország· EU contribution 236 340 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interneuron subtype-specific control of hippocampal memory encoding and retrieval (INSPIRE)

  Universitaetsklinikum Freiburg· Freiburg, Németország· EU contribution 202 125 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Warfare and Agricultural Resilience Nexus in the Ancient Mediterranean (6th. BC - 4th c. AD) (WARNex)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 252 729 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Attentional Control and Mapping in Spatial Navigation: Defining Behavioral Fingerprints for Early Alzheimer’s Risk Detection (SPATIALOS)

  Universitat Jaume I de Castellon· Castellon De La Plana, Spanyolország· EU contribution 209 915 EUR· until 2029. ápr.

• European Commission (Horizon Europe) · HORIZON-ERC

  Principles of UFMylation-driven antibacterial defence (UBACT)

  Universite de Geneve· Geneve, Svájc· EU contribution 1 898 233 EUR· until 2032. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Leveraging long-read RNA-sequencing to understand the pathophysiology of familial and complex Alzheimer’s disease (TranscriptAccuracyAD)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 194 075 EUR· until 2029. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Németország· EU contribution 217 965 EUR· until 2029. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  MineLife: Reconstructing the Social and Environmental History of Eastern Desert Mining Communities (2nd millennium BCE-2nd century AD)

  Centre National de la Recherche Scientifique Cnrs· Paris, Franciaország· EU contribution 226 421 EUR· until 2029. jan.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Multi-scAle high-order neTwork modelling in the stUdy of human aging: A data-dRiven perspectIve using Topology and geometrY (MATURITY)

  Institut National de Recherche En Informatique Et Automatique· Le Chesnay Cedex, Franciaország· EU contribution 226 421 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

10 of 5135 running projects, newest first. Listed amounts together: 321,1 M EUR + 4,3 Mrd USD.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Adaptation and Normalization of a Verbal Episodic Memory Test in French Sign Language

  NCT06902753· Poitiers University Hospital· Frissítve: 2026. okt. 27.

  “Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.

  NCT06523296· Centre Hospitalier Universitaire de Nice· Frissítve: 2026. okt. 23.

  “recruitment challenges”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Frissítve: 2026. okt. 21.

  “Lack of funding”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Frissítve: 2026. okt. 16.

  “poor accrual and funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Frissítve: 2026. szept. 21.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  DECIDE: Dyads and Families

  NCT05139290· Emory University· Frissítve: 2026. szept. 18.

  “No participants were enrolled in the clinical trial portion. The community-engaged nature of the project required more time than anticipated, and funding was insufficient to support the implementation of the proposed intervention.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Implementation of AIP Services for Older Adults With AD

  NCT07361601· Northwestern University· Frissítve: 2026. szept. 14.

  “Not a clinical trial so retiring ClinicalTrials.gov record”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  The Ketogenic Diet for Alzheimer's Disease

  NCT04701957· Assistance Publique - Hôpitaux de Paris· Frissítve: 2026. szept. 10.

  “lake of inclusions”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Vanderbilt University Medical Center· Frissítve: 2026. szept. 9.

  “This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

  NCT05267535· Neurim Pharmaceuticals Ltd.· Frissítve: 2026. szept. 9.

  “Treatment with 20 mg piromelatine did not demonstrate efficacy over treatment with placebo based on analysis with the ADAS-Cog 14 subscale and with other cognitive and neuropsychiatric parameters.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Bristol-Myers Squibb· Forrás

• Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias

  NCT07933367· Rhode Island Hospital· Forrás

• PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

  NCT07169630· National Institute of Mental Health (NIMH)· Forrás

• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Forrás

• The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

  NCT05574400· University of Michigan· Forrás

• Veech Ketone Ester to Support Brain Energy in Mild Cognitive Impairment and Early Alzheimer's Disease

  NCT06767124· University of Pennsylvania· Forrás

• A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by a Genetic Mutation

  2024-517187-36-01· Washington University School Of Medicine· Forrás

• A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)

  NCT07781345· Eisai Limited· Forrás

• CMN LIFU for Enhanced Amyloid Reduction (CLEART Study)

  NCT07866768· University of California, San Francisco· Forrás

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Bristol-Myers Squibb· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 86
• Organoids 36
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 24
• Gene Expression Profiling 176
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 17
• Exome Sequencing 7
• Proteomics 229
• Metabolomics 81
• Mass Spectrometry 62
• Flow Cytometry 16
• Immunohistochemistry 74
• Liquid Biopsy 5
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 676
• Magnetic Resonance Imaging 1001
• Machine Learning 253
• Deep Learning 166
• Cohort Studies 536
• Genome-Wide Association Study 216

• Multi-omics characterization of white matter free water reveals genetic and vascular determinants of neurological disorders.

  Proc Natl Acad Sci U S A, 2026. nov.

• Brain Region-Specific Peptide and Proteomic Signatures Inform Alzheimer's Disease Biomarker Panels.

  J Proteome Res, 2026. nov.

• Integrated N- and O-Glycoproteomics Reveals Site-Specific Glycosylation Dysregulation in Alzheimer's Disease.

  J Proteome Res, 2026. nov.

• Proteomics Reveals Blood-Brain Barrier Membrane Protein Remodeling in Amyloid-β Pathology.

  Mol Pharm, 2026. nov.

• Longitudinal plasma protein profiling in glioblastoma patients using NULISAseq reveals treatment-associated changes across radiation and chemotherapy.

  J Neurooncol, 2026. okt.

• APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer's disease.

  Nat Commun, 2026. okt.

• Mass Spectrometry-Based Structural Proteomics and Analytical Ultracentrifugation Characterize the Structures of Oligomeric Apolipoprotein E4 and Its Variants.

  J Am Soc Mass Spectrom, 2026. okt.

• Integrated Multi-Omics Analysis Reveals ACO2 as an Oxidative-Stress-Related Biomarker in Alzheimer's Disease.

  Biomolecules, 2026. okt.

• Combined Effects of Chlamydia pneumoniae Infection and Hypoxia on Glial Metabolism and Alzheimer's Disease-Related Pathways.

  Int J Mol Sci, 2026. okt.

• Altered Membrane Protein Abundance in the Cerebral Cortex of the JNPL3 Mouse Model of Tauopathy.

  J Proteome Res, 2026. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.